Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases

(PresseBox) - Protagen announced today that a collaboration agreement with Pfizer Inc. has been signed. Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.
Protagen CEO Stefan Müllner comments, "The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team."

PROTAGEN is a pioneer in the development of novel diagnostic products to support personalized therapies, and the clinical development of new drugs in autoimmune diseases. The unique SeroTag® process addresses the unmet need to deliver specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring, and companion diagnostics (CDx). SeroTag® has been successfully employed for marker discovery and patient stratification in various autoimmune diseases such as RA, SLE, MS and related disorders.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: PresseBox
Datum: 03.12.2013 - 10:00 Uhr
Sprache: Deutsch
News-ID 321983
Anzahl Zeichen: 1202

contact information:
Town:

Dortmund

Kategorie:

Electronics & Semiconductors

Diese Pressemitteilung wurde bisher 445 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Protagen Selected by Pfizer to Support Clinical Drug Development of a Novel Compound in Autoimmune Diseases"
steht unter der journalistisch-redaktionellen Verantwortung von

Protagen AG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Protagen AG Sells Service Business ...

07.2013 - Protagen AG, Dortmund, divested its 100% subsidiary Protagen Protein Services GmbH (PPS), to Zukunftsfond Heilbronn. The company was spun out in January 2012 and continued the business of the former operational division Protein Services, wh ...

Protagen counts on Kairos Expertise in Biobank- Management ...

Protagen AG, Dortmund, and Kairos GmbH, Bochum, a specialist in IT solutions for biobank management announced today a marketing & sales cooperation. Both companies are planning for a long term partnership in which Protagen will profit from the c ...

Protagen and NMI announce Co-Development of Multiplex Assays ...

Protagen AG, a specialist in in-vitro diagnostics and the Natural and Medical Sciences Institute at the University of Tübingen (NMI), have announced the signing of an agreement for joint development of multiplex assays for the diagnosis of autoimmu ...

Alle Meldungen von Protagen AG